CN1294911C - Tetrandrine preparation foreyes - Google Patents
Tetrandrine preparation foreyes Download PDFInfo
- Publication number
- CN1294911C CN1294911C CNB200410018612XA CN200410018612A CN1294911C CN 1294911 C CN1294911 C CN 1294911C CN B200410018612X A CNB200410018612X A CN B200410018612XA CN 200410018612 A CN200410018612 A CN 200410018612A CN 1294911 C CN1294911 C CN 1294911C
- Authority
- CN
- China
- Prior art keywords
- tetrandrine
- preparation
- eye
- sodium
- excipient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a tetrandrine preparation for eyes, which belongs to a medical preparing product containing an organic effective component of isoquinoline derivatives. The present invention relates to anti-inflammatory medicament for eyes, which comprises liquid or ointment excipient of eye preparation. The weight percentage of the tetrandrine is from 0.01 to 2%, and the weight percentage of the excipient is from 98 to 99.99%. Prepared tetrandrine eye drops is prepared from tetrandrine, antioxidants, metallic ion complexing agents, osmotic pressure regulating agents, bacteriostatic agents, cosolvent, thickening agents, keratolytics, and water for injection; tetrandrine eye ointment is prepared from tetrandrine, lanolin, liquid paraffin, vaseline; tetrandrine gel-type eye ointment is prepared from tetrandrine, carbomer, trolamine, bacteriostatic agents, antioxidants, metallic ion complexing agents, keratolytics, and water for injection. Compared with the anti-inflammatory medicament for eyes of the prior art, the tetrandrine preparation for eyes has the advantages of high therapeutic effect and small side effect.
Description
Technical field
The present invention relates to the medicine configuration product of the organic active ingredient of isoquinoline-containing derivatives class, specifically is the tetrandrine ophthalmic preparation.
Background technology
In the mechanism of oculopathy, inflammation is the main pathophysiological processes of most of oculopathy, and becomes the major decision sexual factor of disease prognosis.Controlling inflammation is the cardinal principle of Eye disease treating, so inflammation inhibitor is the most frequently used medicine of ophthalmologists, so that control the progress of ophthalmic effectively, it is blind to avoid the patient finally to cause.
Clinical available eye inflammation inhibitor has diclofenac sodium, meticorten and dexamethasone etc. at present.Diclofenac sodium belongs to non-steroid antiinflammatory drug, and local result of use is relatively poor, and the eye zest is bigger, is only applicable to the adjuvant drug of the light oculopathy of minority inflammation.Meticorten, dexamethasone belong to hormones, and the eye inflammation inhibitory action is stronger, clinical comparatively extensive use, but the side effect appearance is more, and harm is bigger, is easy to the recurrence and the state of an illness after the drug withdrawal repeatedly, and the state of an illness heavier person can't effectively control.
Tetrandrine (tetrandrine, Tet) a kind of alkaloid for extracting in the menispermaceous plants Radix stephaniae tetrandrae root has another name called tetrandrine, can separate from Chinese medicine Radix Stephaniae Tetrandrae, Radix stephaniae tetrandrae or Radix Stephaniae Japonicae, be Bisbenzylisoquinolinderivative derivative, mainly be present in the root of Radix Stephaniae Tetrandrae plant Radix stephaniae tetrandrae.Studies show that it has antiinflammatory, analgesia, analgesic, antiallergic, blood pressure lowering, coronary artery dilating, multiple pharmacological effect such as anticancer.Tet begins to be used for the treatment of diseases such as hypertension, pneumosilicosis, hepatic fibrosis the seventies, obtained better curative effect.
National drug standards WS-10001-(HD) 1101-2002 of National Drug Administration's promulgation classifies tetrandrine as rheumatism medicament used as adjuvant drug for antitumor.Tetrandrine tablet WS-10001-(HD-0700)-2002 mostly is coated tablet or Film coated tablets; The main component of tetrandrine injection WS-10001-(HD) 1380-2003 is that tetrandrine hydrochloride (HCMN) 15g, sodium pyrosulfite 1g, sodium chloride 5g, dilute hydrochloric acid are an amount of, disodium edetate, 0.3g, water for injection are an amount of.
Still do not have both at home and abroad and use the report that tetrandrine prepares ophthalmic preparation.
Summary of the invention
The present invention is in order to solve effective treatment of non-bacterial ophthalmia, and a kind of tetrandrine ophthalmic preparation is provided.
Theoretical foundation of the present invention,
Tetrandrine is a kind of alkaloid, and is water insoluble, for this reason, must provide a kind of dissolved lytic agent of tetrandrine that makes, and through screening, hydrochloric acid is a kind of comparatively ideal cosolvent.Sodium pyrosulfite is an antioxidant.The egtazic acid disodium is the complexing of metal ion agent, can eliminate the influence of the metal ion that may exist in the solution, increases the stability of eye drop of the present invention.Sodium chloride is osmotic pressure regulator.HPAA is an antibacterial, to improve the effect duration of eye drop of the present invention.Methylcellulose, or hyprolose, or hyaluronic acid sodium is thickening agent, can prolong drug retention time within the eye.Keatolytics Borneolum Syntheticum or Mentholum can promote that medicine penetrates to ocular tissue.
A kind of tetrandrine ophthalmic preparation comprises the excipient in the ophthalmic preparation, and the weight percent content of the tetrandrine of its ophthalmic preparation is 0.01-2%, and excipient is 98-99.99%.
Described ophthalmic preparation, its tetrandrine eye drop is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Cosolvent 0.1-2mol/L0.5-50ml
Water for injection adds to 1000ml.
Described ophthalmic preparation, its tetrandrine eye drop is made by following raw materials by weight percent,
Tetrandrine 0.01-2%, antioxidant 0.1-0.5%,
Complexing of metal ion agent 0.01-0.05%, osmotic pressure regulator 3.0-8.5%,
Antibacterial 0.004-5%, cosolvent 0.1-2mol/L0.5-50ml,
Thickening agent 0.1-1%, keatolytics 0.01-2%,
Water for injection adds to 1000ml.
Described ophthalmic preparation, its tetrandrine eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
The eye ointment excipient adds to 1000g.
Described ophthalmic preparation, its tetrandrine eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Lanoline 0-20%
Liquid Paraffin 0-20%
Vaseline adds to 1000g.
Described ophthalmic preparation, its tetrandrine type gel-type eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Carbomer 2-10%
Water for injection is to 1000g.
Described ophthalmic preparation, its tetrandrine type gel-type eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Carbomer 2-10%
Triethanolamine 10-17%
Antibacterial 0.004-5%
Antioxidant 0.1-0.5%
Complexing of metal ion agent 0.01-0.05%
Keatolytics 0.01-2%
Water for injection adds to 1000g.
Described ophthalmic preparation, its tetrandrine type gel-type eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Sodium carboxymethyl cellulose 1-6%
Water for injection adds to 1000g.
Described ophthalmic preparation, its tetrandrine type gel-type eye ointment is made by following raw materials by weight percent,
Tetrandrine 0.01-2%
Sodium carboxymethyl cellulose 1-6%
Antibacterial 0.004-5%
Antioxidant 0.1-0.5%
Complexing of metal ion agent 0.01-0.05%
Keatolytics 0.01-2%
Water for injection adds to 1000g.
Described any one ophthalmic preparation is characterized in that directly adopting tetrandrine hydrochloride (HCMN), or the sulphuric acid tetrandrine, or the nitric acid tetrandrine, or phosphoric acid tetrandrine and excipient are made.
Described ophthalmic preparation, its antioxidant is a sodium pyrosulfite, or sodium sulfite, or sodium thiosulfate; The complexing of metal ion agent is a disodium edetate; Osmotic pressure regulator is a sodium chloride, or boric acid; Antibacterial is a sorbic acid, or ethyl hydroxybenzoate; Cosolvent is a hydrochloric acid, or sulphuric acid, or nitric acid, or phosphoric acid; Thickening agent is a methylcellulose, or hyprolose, or hyaluronic acid sodium; Keatolytics is a Borneolum Syntheticum, or Mentholum.
The preparation method of tetrandrine eye drop is with the tetrandrine powder 0.01-2% 0.25mol hydrochloric acid 0.5-50ml dissolving of percentage by weight, obtains the tetrandrine hydrochlorate, and is standby; Antibacterial ethyl hydroxybenzoate 0.03-0.1%, keatolytics Borneolum Syntheticum 0.01-2% be dissolved in 40-80 ℃ the water for injection, add antioxidant sodium pyrosulfite 0.1-0.5%, complexing of metal ion agent disodium edetate 0.01-0.05% and osmotic pressure regulator sodium chloride 3.0-8.5% then, thickening agent 0.1-1% also stirs, after treating its cooling, with tetrandrine hydrochloric acid salt solution mix, add the injection water to 1000ml, mixing, filter, with 100 flowing steam sterilizations 30 minutes, packing, clear, the packing of inspection.
The preparation Preparation Method of tetrandrine eye ointment.
Earlier preparation eye ointment excipient is got liquid Paraffin 0-20% and placed suitable container with lid, and is in 150 ℃ of dry heat sterilizations 1 hour, standby; Other gets lanoline 0-20% and vaseline 60-100%, puts in the suitable container with lid, and heat fused adds the sterilization liquid Paraffin, mixing, and filtered while hot got final product through 150 ℃ of dry heat sterilizations in 1 hour in case of necessity,
Then,, get and add a small amount of sterilization liquid Paraffin in the mortar that tetrandrine 0.01-2% puts sterilization and be ground into thin pasty state according to aseptic manipulation, gradation add the eye ointment excipient to 1000g with adding with grinding well, be sub-packed in the eye ointment pipe promptly.
The preparation Preparation Method of tetrandrine eye ointment.
Get tetrandrine 0.01-2% and put in the sterilization mortar, be ground into fine powder, cross sieve No. 8, standby;
Get the eye ointment excipient after the sterilization, heating makes eye pasting substrate keep molten state under aseptic condition, and tetrandrine fine powder sterile working is added, and stirs to ointment to form.
The preparation Preparation Method of tetrandrine eye ointment.
Get the hydrochloric acid that tetrandrine 0.01-2% adds concentration 0.1-2mol/L according to aseptic manipulation, or nitric acid, or sulphuric acid, or phosphoric acid 0.5-50ml dissolving, add that a small amount of excipient grinds and absorbed fully to aqueous solution, add residue sterilization eye pasting substrate more gradually.
The preparation method of tetrandrine type gel-type eye ointment.
Get the hydrochloric acid that tetrandrine 0.01-2% adds dilute concentration 0.1-2mol/L by weight percentage, or nitric acid, or sulphuric acid, or phosphoric acid 0.5-50ml dissolving, standby; Other gets antibacterial 0.004-5%, antioxidant 0.1-0.5%, metal chelating agent 0.01-0.05%, keatolytics 0.01-2% are dissolved in the suitable quantity of water, after adding the abundant swelling of carbomer 2-10%, add triethanolamine 10-17% and form the gel excipient, the tetrandrine that dissolving is good joins in the above-mentioned gel excipient, add the injection water to 1000g, mix homogeneously, deaeration; In 100-125 ℃ of flowing steam sterilization 30-60 minute, be sub-packed in after the cooling in the eye ointment pipe promptly.
The preparation method of tetrandrine type gel-type eye ointment.
Get the hydrochloric acid that tetrandrine 0.01-2% adds concentration 0.1-2mol/L by weight percentage, or nitric acid, or sulphuric acid, or phosphoric acid 0.5-50ml dissolving is standby; Other gets antibacterial 0.004-5%, antioxidant 0.1-0.5%, metal chelating agent 0.01-0.05%, keatolytics 0.01-2% are dissolved in the suitable quantity of water, in water-bath, be heated to 40-80 ℃, after adding the abundant swelling of sodium carboxymethyl cellulose 20-50%, stirring and dissolving, the tetrandrine that dissolving is good joins in the above-mentioned gel excipient, adds the injection water to 1000g, mix homogeneously, deaeration. in 100-125 ℃ of flowing steam sterilization 30-60 minute, be sub-packed in after the cooling in the eye ointment pipe promptly.
Prove that through clinical trial tetrandrine ophthalmic preparation of the present invention and oneself have the ophthalmology antibiotic medicine of technology to compare, it has the curative effect height, and stability of drug products is good, the advantage that side effect is little.
The specific embodiment
A kind of preparation method of tetrandrine ophthalmic preparation, its tetrandrine eye drop are that tetrandrine powder 1g is dissolved with 0.25mol hydrochloric acid 10-20ml, obtain the tetrandrine hydrochlorate, and be standby; Ethyl hydroxybenzoate 0.3g, Borneolum Syntheticum 0.05g be dissolved in 50-70 ℃ the water for injection, add sodium pyrosulfite 1g, disodium edetate 0.3 and sodium chloride 6.3g then, hyprolose 0.5g also stirs, after treating its cooling, mix, add the injection water to 1000ml with the tetrandrine hydrochlorate, mixing, filter, with 90-110 ℃ flowing steam sterilization 30-40 minute, packing, clear, the packing of inspection.
A kind of preparation Preparation Method of tetrandrine eye ointment.
Earlier preparation eye ointment excipient is got liquid Paraffin 100g and placed suitable container with lid, and is in 140-160 ℃ of dry heat sterilization 1 hour, standby; Other gets lanoline 100g and vaseline 800g, puts in the suitable container with lid, and heat fused adds the sterilization liquid Paraffin, mixing, and filtered while hot got final product through 150 ℃ of dry heat sterilizations in 1 hour in case of necessity.
Then,, get and add a small amount of sterilization liquid Paraffin in the mortar that tetrandrine 1g puts sterilization and be ground into thin pasty state according to aseptic manipulation, gradation add the eye ointment excipient to 1000g with adding with grinding well, be sub-packed in the eye ointment pipe promptly.
A kind of preparation Preparation Method of tetrandrine eye ointment.
Get tetrandrine 1g and put in the sterilization mortar, be ground into fine powder, cross sieve No. 8, standby;
Get the eye ointment excipient after the sterilization, heating makes the eye ointment excipient keep molten state 999g under aseptic condition, with the adding of tetrandrine fine powder 1g sterile working, stirs to ointment and forms.
A kind of preparation Preparation Method of tetrandrine eye ointment.
Get the hydrochloric acid that tetrandrine 1g adds concentration 0.1-2mol/L according to aseptic manipulation, or nitric acid, or sulphuric acid, or phosphoric acid 0.5-50ml dissolving, add that a small amount of excipient grinds and absorbed fully to aqueous solution, add residue sterilization eye ointment excipient more gradually to 1000g.
A kind of preparation method of tetrandrine type gel-type eye ointment.
Get the hydrochloric acid that tetrandrine 1g adds concentration 0.1-2mol/L by weight percentage, or nitric acid, or sulphuric acid, or phosphoric acid 0.5-50ml dissolving, standby; Other gets antibacterial ethyl hydroxybenzoate 0.3g, antioxidant sodium pyrosulfite 1g, metal chelating agent disodium edetate 0.3g, keatolytics Borneolum Syntheticum 0.05g are dissolved in the suitable quantity of water, after adding the abundant swelling of carbomer 40g, add triethanolamine 13.5g and form the gel excipient, the tetrandrine that dissolving is good joins in the above-mentioned gel excipient, add the injection water to 1000g, mix homogeneously, deaeration; In 100 ℃ of flowing steam sterilizations 30 minutes, be sub-packed in after the cooling in the eye ointment pipe promptly.
A kind of preparation method of tetrandrine type gel-type eye ointment.
Getting tetrandrine 1g by weight percentage, to add 0.25mol/ml hydrochloric acid 10-20ml dissolving standby; Other gets antibacterial ethyl hydroxybenzoate 0.3g, keatolytics Borneolum Syntheticum 0.05g, antioxidant sodium pyrosulfite 1g, metal chelating agent disodium edetate 0.3g are dissolved in the suitable quantity of water, in water-bath, be heated to 50-70 ℃, after adding the abundant swelling of sodium carboxymethyl cellulose 30g, stirring and dissolving, the tetrandrine that dissolving is good joins in the above-mentioned gel excipient, adds injection water 1000g, mix homogeneously, deaeration. in 100 ℃ of flowing steam sterilizations 30 minutes, be sub-packed in after the cooling in the eye ointment pipe promptly.
Described ophthalmic preparation, its antioxidant is a sodium pyrosulfite, or sodium sulfite, or sodium thiosulfate; The complexing of metal ion agent is a disodium edetate; Osmotic pressure regulator is a sodium chloride, or boric acid; Antibacterial is a sorbic acid, or ethyl hydroxybenzoate; Cosolvent is a hydrochloric acid, or sulphuric acid, or nitric acid, or phosphoric acid; Thickening agent is a methylcellulose, or hyprolose, or hyaluronic acid sodium.
Described ophthalmic preparation directly adopts tetrandrine hydrochloride (HCMN), or the sulphuric acid tetrandrine, or the nitric acid tetrandrine, or phosphoric acid tetrandrine and excipient make, and then needn't use tetrandrine to add cosolvent.
Described antibacterial Benzene Chloride first hydrocarbon acid 0.004-0.02%; Or phenylmercuric nitrate 0.002-0.05%; Or phenylmercuric acetate 0.005-0.02, with 1/2 water 40-50 ℃ dissolving; Or three glass container of packing into after the neoprene tertiary alcohol 0.25-0.5% heating for dissolving; Or thimerosal 0.01-0.02% dissolving; Or hibitane 0.02%; Or mercuric oxycyanide 0.01-0.02%; Or oxybenzene first, second, third, butyl ester 0.03-0.1%; Or phenethanol 0.25-0.5%; Or sorbic acid 0.01-0.2%.
The 0.1-0.5% that described sodium sulfite is weight percentage.
The 0.1-0.5% that described sodium thiosulfate is weight percentage.
Described thickening agent methylcellulose, concentration range 0.1-1%; The hyprolose concentration range is 0.5-1.0%.
Table 1 is listed to be the influence of hydrochloric acid addition to drug solubility.Get tetrandrine 0.1g, add not commensurability 0.5mol/L hydrochloric acid, make its dissolving, add and steam Evaporated water, observe the dissolving situation under room temperature and cryogenic conditions to the 100ml mixing.
Table 1 hydrochloric acid addition is to the influence of tetrandrine dissolubility:
| Addition ml | 0.3 | 0.4 | 0.5 | 0.6 |
| Room temperature | Dissolved particles not | Dissolved particles not | Dissolved particles not | Solution is clear and bright |
| Cryopreservation 24h | - | - | - | Solution is clear and bright |
Variable concentrations hydrochloric acid is to the dissolved influence of tetrandrine.During screening, get tetrandrine 0.1g respectively, add variable concentrations etc. behind the dissolve with hydrochloric acid solution of amount adding distil water to 100ml, and get partly to do and strengthen (90 ℃ of transconversion into heat tests, 4h) and exposure experiments to light (daylight down irradiation 10 days), observe the variation of its outward appearance and pH value, the results are shown in Table 2.
The influence of table 2 variable concentrations hydrochloric acid:
| HCl(mol/L) | Illumination | 90℃ | pH | Operability |
| 0.125 | YG-1 | YG-3 | 3.99 | Better |
| 0,25 | YG-1 | YG-3 | 4.04 | Good |
| 0.5 | YG-1 | YG-3 | 4.11 | Better |
| 1 | YG-1 | YG-3 | 3.97 | Better |
| 2 | YG-1 | YG-3 | 4.09 | Good |
From above-mentioned table listed result as can be seen, concentration of hydrochloric acid is best with 0.25mol/L.
Antioxidant is to the influence of preparation stability.Press following five kinds of prescription formulated:
1, tetrandrine 0.1g with dissolving with hydrochloric acid after, adding distil water 100ml;
2, tetrandrine 0.1g with dissolving with hydrochloric acid after, add normal saline to 100ml;
3, compound method adds disodium edetate (EDTA) 0.03g with 1;
4, compound method adds sodium pyrosulfite 0.1g with 1;
5, compound method adds sodium pyrosulfite 0.1g and EDTA 0.03g with 1.
With the preparation of above-mentioned five kinds of prescription preparations do the heating strenuous test (90 ℃ or 80 ℃, 4h) and exposure experiments to light (daylight irradiation 10 days) down, observe its cosmetic variation, the results are shown in Table 3:
Table 3 antioxidant is to the influence of preparation stability
| Prescription 1 | Prescription 2 | Prescription 3 | Prescription 4 | Prescription 5 | ||
| 90℃ | Colorimetric | YG-3 | YG-3 | YG-2 | YG-2 | YG-1 |
| 90℃ | Clarity | Clear and bright | Clear and bright | Clear and bright | Clear and bright | Clear and bright |
| 80℃ | Colorimetric | YG-1 | YG-1 | YG-1 | YG-1 | YG-1 |
| 80℃ | Clarity | Clear and bright | Clear and bright | Clear and bright | Clear and bright | Clear and bright |
| Exposure experiments to light | Colorimetric | YG-2 | YG-2 | YG-1 | YG-1 | YG-1 |
| Exposure experiments to light | Clarity | Clear and bright | Clear and bright | Clear and bright | Clear and bright | Clear and bright |
The above results shows that sodium pyrosulfite and EDTA share and can strengthen stability of formulation, selects prescription 5 to be advisable.
Preparation method:
1. get tetrandrine 1g, make the tetrandrine hydrochlorate with the 0.25mol/L dissolving with hydrochloric acid;
2. get in the water for injection that ethyl hydroxybenzoate is dissolved in 70 ℃;
3. in ethyl hydroxybenzoate solution, add sodium pyrosulfite 1g, disodium edetate 0.3g, and sodium chloride 6,3g is also stirred, and makes it dissolving;
4. after treating the solution cooling of abovementioned steps, mix with the tetrandrine hydrochlorate, water for injection adds to 1000ml, and even mixing;
5. filter;
6. with 100 ℃ of flowing steam sterilizations 30 minutes;
7. packing, clear, the packing of inspection.
The study on the stability of Zhi Bei tetrandrine eye drop as stated above.The tetrandrine eye drop of preparation was placed under room temperature or the high temperature after 5 or 10 hours, observe outward appearance, PH and changes of contents, its result is as shown in table 4:
The stability test result of table 4 preparation under intensified condition
| 5h | 5h | 10h | 10h | ||
| Lot number | Condition | PH | Relative labelled amount % | PH | Relative labelled amount % |
| 1 | Room temperature | 4.86 | 99.95 | 4.90 | 99.60 |
| 2 | 4.90 | 100.30 | 4.89 | 99.51 | |
| 3 | 4.80 | 100.01 | 4.83 | 99.25 |
| 1 | 80℃ | 4.80 | 100.13 | 4.90 | 98.83 |
| 2 | 4.92 | 97.45 | 4.78 | 100.51 | |
| 3 | 4.78 | 98.12 | 4.90 | 97.81 | |
| 1 | 90℃ | 4.84 | 100.11 | 4.86 | 97.83 |
| 2 | 4.89 | 101.79 | 4.80 | 99.25 | |
| 3 | 4.79 | 98.64 | 4.79 | 99.90 |
From result shown in the table 4, prove that Radix Stephaniae Tetrandrae first Chinese eye drop of the present invention does not all have significant change on outward appearance, pH value and content.
1 experimental uveitic therapeutical effect.
Uveitis is a kind of common clinically autoimmune disease.Bring out the rabbit experiment uveitis with bovine serum albumin, tetrandrine (50mg/kgd, ip) and dexamethasone (5mg/kgd, ip) treatment 8d, can significantly reduce eye inflammation reaction, waterproof protein content, serum immune complex and peripheral T lymphocyte conversion ratio.Stop 4d after the administration, Dexamethasone group aqueous humor protein and serum immune complex raise once again.Though the tetrandrine group has rising, be evident as low than Dexamethasone group.Pathological examination finds that tetrandrine group venation inflammation is evident as gently than matched group.
The inflammation rank of each treated animal of table 5 (X ± SD)
| Group number | Group | The eye number | The inflammation rank | Suppression ratio % | F | P |
| 1 2 3 | Medication dexamethasone tetrandrine not | 12 12 12 | 3.75±0.75 1.08±0.51 1.42±0.51 | - 71.2 62.1 | 36.21 | ＜0.001 |
Table 5 shows: tetrandrine does not relatively have significant difference to the inhibition and the dexamethasone of clinical inflammation feature.
The waterproof protein content of each treated animal of table 6 (X ± SD)
| Group number | Group | The eye number | The inflammation rank | Suppression ratio % | F | P |
| 1 2 3 4 | Normal control is medication dexamethasone tetrandrine not | 12 12 12 12 | 0.78±0.09 14.33±1.21 4.43±1.64 5.95±1.63 | - - 73.8 61.8 | 91.18 | ＜0.01 |
Table 6 shows that the aqueous humor protein content of tetrandrine and dexamethasone does not have significant difference, all significantly is lower than the medication group, shows that tetrandrine has also obviously suppressed aqueous humor protein content and increased.
The result shows that tetrandrine suppresses experimental uveitis, and is also relevant with cell immune response with its inhibition body fluid except its antiinflammatory action, and do not cause knock-on after the drug withdrawal.Tetrandrine also significantly suppresses the Mus uveitis that endotoxin and IL-1-α cause by the noncompetitive mode.
The effect of 2 corneal inflammation.
Though cornea does not have blood vessel, immunoreactive various compositions such as immunoglobulin, complement, T cell, B cell etc. still are present in cornea, illustrate that cornea itself has normal immune system.Observe the effect of tetrandrine to the experimental herpes simplex keratitis of Mus by experiment, the results suggest whole body is used tetrandrine can be by modifying the development of host to immunity/inflammatory reaction adjusting Mus herpetic keratitis of virus.Further adopt the reverse transcription PCR method to detect the discovery normal cornea and do not express IL-1 β, TNF α mRNA, after viral infection is inflamed, then express the two.And it is infected but only express TNF α mRNA through the tetrandrine treatment person of not being inflamed.It is necessary that prompting local I L-1 β and TNF α expression of gene are that institute takes place keratitis, and tetrandrine is by suppressing the inflammatory reaction that IL-1 β generates cornea after the infection that alleviates the herpes simplex disease.
The effect of 3 pairs of anaphylaxis conjunctivitises.
The experimental conjunctivitis of sinomenine (TDR) has therapeutical effect.
The SWR/J mice group is as follows: group one is the normal control group; Group two is sensitization but does not treat group; Group three is buffering saline solution (BS) the treatment group of sensitization; Group four is the TDR treatment group of sensitization.The back is passed through local nose for three groups and is contacted artemisiifolia with the conjunctiva mucosa, and allergen excites the conjunctiva modeling.Group three and group four are accepted BS and TDR treatment respectively.Pass judgment on the anaphylaxis conjunctivitis curative effect by clinical sign and histopathology scoring.The mRNA gene expression of polymerase chain reaction,PCR (PCR) technical Analysis conjunctiva interleukin 1 β (IL-1 β) and IL-5.All confirm to suffer from anaphylaxis conjunctivitis on the clinical and histology of the mice of all artemisiifolia modelings.By giving the inflammatory reaction that TDR has obviously suppressed conjunctiva.Histopathological analysis proof TDR has significantly alleviated oxyphil cell's infiltration of conjunctiva, and has significantly reduced the mastocyte number of complete threshing.Compare with not treatment group and BS treatment group, TDR treatment group mice conjunctiva IL-1 β and IL-5 mRNA gene expression are significantly reduced.See Table, the result shows that TDR treatment conjunctivitis has potent clinical effect.
Experiment shows, can adjust the anaphylaxis conjunctivitis that ragweed pollen causes significantly to injection tetrandrine in the mouse peritoneum.
The scoring of table 7 clinical sign
| Group | n | Clinical score | The p value |
| Not treatment group of normal control group BS treatment group TDR treatment group | 20 20 20 20 | 0 3.0±0.7 2.9±0.4 2.4±0.4 | p＜0.05 * |
*Between TDR treatment group and the not treatment group mice (p＜0.05), on (p＜0.05) statistics significant difference is arranged between TDR treatment group and the BS treatment group mice.
Table 8 histopathology is * as a result
| Group | n | The oxyphil cell | The mastocyte sum | The mastocyte number of threshing |
| Normally do not treat BS TDR | 15 15 15 15 | 53.3±53.3 2185.3±1545.7 1918.8±906.1 768.0±421.0 + | 373.1±106.6 906.1±319.8 852.8±266.5 639.6±53.3 + | 53.3±53.3 373.1±213.2 319.8±159.9 1061.6±106.6 ++ |
*Value: average cell number/mm3 (± SD)
On (p＜0.05 and p＜0.01) statistics significant difference is arranged between TDR treatment group and not treatment group or the BS treatment group mice.
The oxyphil cell that histopathological analysis proof tetrandrine can reduce conjunctiva significantly infiltrates and cytomegalic quantity complete and threshing.Mice after the tetrandrine treatment, the gene expression of IL-1 β and IL-5 mRNA has obvious downward modulation than the mice of buffer treatment.
The inhibitory action of 4 pairs of experimental preceding uveitiies.
The preceding uveitis that crystalline protein causes mainly betides iris and corpus ciliare.Experiment shows that tetrandrine (50mg/kg) can significantly delay and suppress the inflammatory reaction of uveitis before the rabbit that crystalline protein causes, and prostaglandin E total amount in the reduction iris suppresses leukocytic oozing out, and the intraocular pressure that can not raise.Pathological examination finds that the inflammatory reaction of iris is obviously light than matched group, and local eye drip does not have obvious inhibitory action to the iris inflammation.Its anti-inflammatory mechanisms is main relevant with the calcium antagonism of tetrandrine.
Table 9 clinical manifestation scoring
| Group | N | Clinical score | The P value |
| Not medication group of normal group buffer solution group sinomenine group | 20 20 20 20 | 0 3.0±0.6 2.9±0.5 2.2±0.4 | ＜0.05 * |
*With do not treat and cushion the treatment mouse relatively
Table 10 histopathology result
*
| Group | n | Acidophilia's property | Total rod cell | Non-graininess rod cell |
| The normal untreated buffer solution tetrandrine of raising | 15 15 15 15 | 53±53 2185±1545 1919±906 768±421 ++ | 373±106 906±319 853±266 693±53 + | 53±53 373±213 319±159 106±106 + |
* every mm
2The cell number meansigma methods (± SD)
Statistics goes up effective difference (P＜0.05) between+treatment group and untreated or the buffer solution treatment group
++(P＜0.01)
Experiment shows that tetrandrine can effectively suppress the inflammatory corneal injury that I-type herpes simplex virus brings out in the BALB/C mice.SWR/J rathole conjunctiva forms allergic conjunctivitis after ragweed pollen sensitization, its symptom and histopathology characteristic remarkable reduce after the tetrandrine treatment.The above results shows that tetrandrine is to the conjunctivitis therapeutical effect.
The acute toxicity test of tetrandrine ophthalmic preparation.
Tetrandrine eye drop irritation test.
1. test objective; Observe the animal eyes contact and tried the irritant reaction situation that produced behind the thing.
2. animal: rabbit, 10, body weight 2～3kg.
3. tried thing: tetrandrine eye drop, excipient.
4. test method: will be tried thing and splash into or be coated in the branch hole conjunctival sac, dosage 0.1ml, opposite side do the excipient contrast.Every day 4 times, continuous 7 days, give tried thing after, with hands with passive closed 5～10 seconds of animal eyelid.The local response situation tried behind the thing 6,24,48,72 hours to 14 days given in record.
5. the result judges and estimates: by table 11,12 each animal is contacted the irritant reaction score value addition of cornea, iris and conjunctiva afterwards with trying thing, be the total mark that this is tried the thing irritant reaction.The irritant reaction total mark of each animal subject with divided by number of animals, be the last score value that this is tried the thing eye irritation.According to said method try to achieve respectively, stimulate score value for the eye tried behind the thing 6,24,72 hours to 14 days, and be as the criterion, press table 11,12 standards, judge the eye irritation degree of trying thing with highest score.
Table 11 an irritant reaction scoring
| The eye irritant reaction | Score value |
| The no muddiness of the corneal opacity (being as the criterion with the finest and close position) is dispersed in or the diffusivity muddiness, the high-visible translucent areas of iris is easily differentiated, iris is smudgy the canescence translucent areas to occur, the iris details is unclear, the reluctantly visible cornea of pupil size is opaque, because muddy, iris is beyond recognition.The normal gauffer of iris is obviously deepened, congested, swelling, mild hyperaemia is arranged around the cornea, pupil still responds to light, hemorrhage, naked eyes are as seen downright bad, to light reactionless (or wherein a kind of pathological reaction occurring) conjunctiva A, hyperemia (refers to palpebral conjunctiva, the bulbar conjunctiva position) hyperemia of blood vessel normal blood vessels is the cerise congestion of blood vessel and is peony, blood vessel is difficult for differentiating diffusivity hyperemia and is aubergine B, edema does not have obviously edema of the slight edema of edema (comprising instant embrane), causes the nearly semi-closed edema of a face to eye face and surpasses semi-closed C with the part conjunctiva edema of turning up, secretions does not have a small amount of secretions secretions of secretions makes eyelid and eyelashes humidity or adhesion secretions make the moist or total mark of adhering in whole eye district | 0 1 2 3 4 0 1 2 0 1 2 3 0 1 2 3 4 0 1 2 3 16 |
Table 12 a stimulation evaluation criterion
| Integration | |
| Zest moderate zest intensity zest that nonirritant is slight | 0-3 4-8 9-12 13-16 |
6. result of the test: tetrandrine rabbit eye irritation result of the test sees Table 13.
Table 13 tetrandrine eye drop adds lagophthalmos irritation test appraisal result
| 6h | 24h | 48h | 72h | 4d | 5d | 6d | 7d | |||||||||
| Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | |
| Total mark | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 6 | 1 | 0 | 0 |
| Average mark | 0.2 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 | 0.1 | 0 | 0.3 | 0 | 0.6 | 0.1 | 0 | 0 |
| 8d | 9d | 10d | 11d | 12d | 13d | 14d | ||||||||||
| Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | Preparation | Contrast | |||
| Total mark | 0 | 0 | 1 | 0 | 2 | 1 | 3 | 0 | 4 | 1 | 3 | 1 | 1 | 0 | ||
| Average mark | 0 | 0 | 0.1 | 0 | 0.2 | 0.1 | 0.3 | 0 | 0.4 | 0.1 | 0.3 | 0.1 | 0.1 | 0 | ||
7. conclusion: above-mentioned experimental result as seen, irritation test integration＜3, the tetrandrine eye drop nonirritant that provides.
Claims (1)
1. tetrandrine ophthalmic preparation is characterized in that the tetrandrine eye drop makes by following raw materials by weight percent,
Tetrandrine 0.01-2%, antioxidant 0.1-0.5%,
Complexing of metal ion agent 0.01-0.05%, osmotic pressure regulator 3.0-8.5%,
Antibacterial 0.004-5%, cosolvent 0.1-2mol/L 0.5-50ml,
Thickening agent 0.1-1%, keatolytics 0.01-2%,
Water for injection adds to 1000ml,
Antioxidant wherein is a sodium pyrosulfite, or sodium sulfite, or sodium thiosulfate; The complexing of metal ion agent is a disodium edetate; Osmotic pressure regulator is a sodium chloride, or boric acid; Antibacterial is a sorbic acid, or ethyl hydroxybenzoate; Cosolvent is a hydrochloric acid; Thickening agent is a methylcellulose, or hyprolose, or hyaluronic acid sodium; Keatolytics is a Borneolum Syntheticum, or Mentholum.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410018612XA CN1294911C (en) | 2004-01-13 | 2004-01-13 | Tetrandrine preparation foreyes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB200410018612XA CN1294911C (en) | 2004-01-13 | 2004-01-13 | Tetrandrine preparation foreyes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1640401A CN1640401A (en) | 2005-07-20 |
| CN1294911C true CN1294911C (en) | 2007-01-17 |
Family
ID=34868238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200410018612XA Expired - Fee Related CN1294911C (en) | 2004-01-13 | 2004-01-13 | Tetrandrine preparation foreyes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1294911C (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105726484B (en) * | 2016-02-25 | 2018-06-08 | 天津中医药大学 | A kind of tetrandrine liquid crystal nanoparticle eye-drops preparations and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187123A (en) * | 1995-04-11 | 1998-07-08 | 马萨诸塞眼科耳科诊所 | Treatment for ocular inflammation |
-
2004
- 2004-01-13 CN CNB200410018612XA patent/CN1294911C/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1187123A (en) * | 1995-04-11 | 1998-07-08 | 马萨诸塞眼科耳科诊所 | Treatment for ocular inflammation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1640401A (en) | 2005-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1241569C (en) | Novel combination of non sedative anti histamines containing substances which influence the action of leukotriene, for treating rhinitis/conjuncitivitis | |
| CA3077362A1 (en) | Treatment of inflammatory disorders | |
| WO2008053982A1 (en) | Composition for treating allergy | |
| JP5897592B2 (en) | Folic acid-ramipril combination: cytoprotective, neuroprotective, and retinal protective ophthalmic composition | |
| CN108785251B (en) | Medicinal composition for eyes and preparation method and application thereof | |
| CN1870997A (en) | Treatment agent for keratoconjunctival disorder | |
| CN114588156B (en) | Ophthalmic preparation and application thereof in treating presbyopia | |
| JPH0368006B2 (en) | ||
| CN102362924A (en) | Medicinal composition for treating ophthalmic diseases and preparation method thereof | |
| RU2281086C1 (en) | Ophthalmic anti-histaminic drops | |
| CN1895281A (en) | Chinese-medicinal preparation and making method for treating acute corneitis and releasing visual fatigue | |
| CN1270707C (en) | Ophthalmic solution | |
| CN1294911C (en) | Tetrandrine preparation foreyes | |
| CN1785192A (en) | Eye-drops prepns. contg. tetrandrine and its application for preparing medicine therewith | |
| CN1965825A (en) | Ocular surface applied medicament for treating eyes immunological disease and inhibiting proliferation and neovascularization | |
| CN1016313B (en) | Pharmaceutical composition for treatment of cataract | |
| CN102512467A (en) | Ophthalmic preparation of panax notoginseng saponins and preparation method thereof | |
| CN1186336C (en) | Prepn and application in preparing medicine of fraxinus general coumarin | |
| CN101036659A (en) | A group of epinastine hydrochloride agent and the method for preparing the same | |
| CN100335035C (en) | Preparation method and application of Chinese medicinal preparation for ophthalmology | |
| CN1868523A (en) | Medicine composition for treating eye disease, and its use | |
| CN1830462A (en) | Erycibes extraction, medicinal composition containing said oxtraction and its preparation method | |
| CN1108095A (en) | Composition for prophylaxis and treatment of myopia | |
| CN1923203A (en) | Boletic acid ketotifen eye drops containing sodium hyaluronate and its preparing process | |
| CN1148810A (en) | Medicinal composition for treating glaucoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070117 Termination date: 20110113 |